Corvus Capital Ltd. has made a significant move in the market by proposing to acquire CDT Equity Inc. at a price of $2.00 per share. This offer comes as a response to concerns regarding the undervaluation of CDT's assets and its current market performance. The proposal, delivered in a letter to CDT's board of directors, aims to engage in discussions about enhancing shareholder value amidst ongoing capital raising challenges.

As of November 5, 2026, Corvus Capital, through its ownership of shares, has become the largest shareholder of CDT Equity Inc., holding approximately 22.1% of the company's outstanding shares. This acquisition proposal is seen as a strategic effort to address the disparity between the company's market valuation and the value of its assets.

Background

Corvus Capital Ltd. is a company incorporated in the Cayman Islands, with its business address at Willow House, Cricket Square, Grand Cayman. The firm is primarily involved in investment activities, and its recent filings have indicated a focus on acquiring significant stakes in companies within the pharmaceutical sector.

CDT Equity Inc., formerly known as Conduit Pharmaceuticals Inc., operates in the pharmaceutical preparations sector. The company has faced challenges related to its market valuation and capital raising activities, which have prompted Corvus Capital's recent actions. The latest filing, made on November 6, 2026, is an amendment to a previous Schedule 13D, outlining Corvus Capital's intentions regarding its investment in CDT.

What the Filing Says

The recent filing indicates that Corvus Capital intends to acquire all outstanding shares of CDT not already owned by them at a proposed price of $2.00 per share. This price represents a substantial premium over the company's recent market valuation, which closed at $1.018 on November 4, 2026. The proposal is part of a broader strategy to engage with CDT's board regarding potential transactions that could enhance shareholder value.

In the letter to CDT's board, Andrew Regan, CEO of Corvus, expressed concerns about the company's market valuation and urged the board to consider suspending its at-the-market offering program while evaluating the proposal. Regan also recommended the formation of a committee of independent directors to assess the potential acquisition and other strategic alternatives.

Impact

This proposal could significantly impact shareholders of CDT Equity Inc., as it aims to address the perceived undervaluation of the company's assets. With Corvus Capital owning a substantial stake, the outcome of these discussions will likely influence the company's future direction and governance. Additionally, the proposal may affect other stakeholders in the pharmaceutical preparations sector, highlighting ongoing challenges in capital raising and market perception.

What's Next

Following this filing, it remains to be seen how CDT's board will respond to Corvus Capital's proposal. The filing does not specify the next steps, but it indicates that Corvus intends to continue reviewing its investment in CDT and may engage in further discussions with the board regarding the potential transaction.